Loading...
Market
How many major pharmaceutical companies will announce similar perioperative treatments for muscle-invasive bladder cancer by end of 2025?
2
Resolution / Starting Odds
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Announcements from major pharmaceutical companies and clinical trial databases
Story
AstraZeneca's Imfinzi Shows Promise in Bladder Cancer Treatment
Sep 15, 2024, 02:35 PM
AstraZeneca's Imfinzi (durvalumab) has shown promising results in treating muscle-invasive bladder cancer. In the NIAGARA Phase III trial, the perioperative regimen of Imfinzi reduced the risk of recurrence by 32% and the risk of death by 25% compared to neoadjuvant chemotherapy alone. These findings suggest that Imfinzi could potentially extend the lives of bladder cancer patients and open up a new market for the blockbuster medicine. The study's results were highlighted at the ESMO 2024 conference.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
0-2 companies • 25%
3-5 companies • 25%
6-8 companies • 25%
More than 8 companies • 25%
0 companies • 25%
1-2 companies • 25%
3-4 companies • 25%
5 or more companies • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1-2 companies • 25%
3-5 companies • 25%
More than 5 companies • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
Pfizer • 25%
Roche • 25%
Johnson & Johnson • 25%
Novartis • 25%
None • 25%
1 to 2 • 25%
3 to 4 • 25%
More than 4 • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Eli Lilly • 25%
Both • 25%
Neither • 25%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%